Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201211044 Principal Investigator: Linette, Gerald
Title: A Randomized, Open-Label Phase III Trial of BMS-936558 versus Investigator’s Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy
Phase: III Disease Site: Melanoma, Skin
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this study is to test the effectiveness, safety, and tolerability
of an investigational drug called BMS-936558.
The effectiveness of BMS-936558 in melanoma will be determined by comparing the observed change in tumor size and the survival of participants who receive the investigational drug BMS-936558 to those who receive your study doctor’s choice of either
dacarbazine or paclitaxel plus carboplatin.
 
More Information:
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)